Recombinant Humanized anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2/neu Overexpressing Human Breast Cancer Xenografts

摘要: Recombinant humanized anti-HER2 antibody, rhuMAb HER2, inhibits the growth of breast cancer cells overexpressing HER2 and has clinical activity. We explored in preclinical models its capacity to enhance tumoricidal effects paclitaxel doxorubicin. In cultures naturally HER2-overexpressing cells, inhibited enhanced cytotoxic paclitaxel. Treatment well established BT-474 xenografts athymic mice with resulted a dose-dependent antitumor combination studies, treatment or doxorubicin greater inhibition than that observed any agent alone. The highest tumor had significantly superior complete regression rate when compared either Clinical trials are built on these results under way.